Newsfeeds - Spark Newswire

1 minute read

Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $285

Today, 5:10 PM

Morgan Stanley analyst Matthew Harrison maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Equal-Weight and raises the price target from $253 to $285.

VRTX

1 minute read

RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $288

By Benzinga Newsdesk

Today, 5:10 PM

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Sector Perform and raises the price target from $281 to $288.

VRTX

1 minute read

Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $335

By Benzinga Newsdesk

Today, 5:10 PM

Wells Fargo analyst Mohit Bansal maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $305 to $335.

VRTX

2 minute read

Vertex Pharmaceuticals Unusual Options Activity For October 27

By Benzinga Insights

Today, 5:10 PM

A whale with a lot of money to spend has taken a noticeably bearish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals (NASDAQ:VRTX) we detected 13 strange trades.

VRTX

18 minute read

Earnings

Earnings Scheduled For October 27, 2022

By Benzinga Insights

Today, 5:10 PM

Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.

AAPL

2 minute read

Analyst Ratings

Analyst Ratings for Vertex Pharmaceuticals

By Benzinga Insights

Today, 5:10 PM

Over the past 3 months, 5 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

VRTX

1 minute read

JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $327

By Benzinga Newsdesk

Today, 5:10 PM

JP Morgan analyst Jessica Fye maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $319 to $327.

VRTX

1 minute read

If You Invested $100 In This Stock 15 Years Ago, You Would Have $900 Today

By Benzinga Insights

Today, 5:10 PM

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 9.87% on an annualized basis producing an average annual return of 15.93%. Currently, Vertex Pharmaceuticals has a market capitalization of $75.99 billion.

VRTX

1 minute read

MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders

By Vandana Singh

Today, 5:10 PM

MaxCyte Inc (NASDAQ: MXCT) has signed a

CRSP

1 minute read

$1000 Invested In This Stock 15 Years Ago Would Be Worth $7,400 Today

By Benzinga Insights

Today, 5:10 PM

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 8.2% on an annualized basis producing an average annual return of 14.17%. Currently, Vertex Pharmaceuticals has a market capitalization of $72.97 billion.

VRTX